logo

For the Inventor, By the Inventor

La Chaux-de-Fonds, Switzerland

Glenmark Pharmaceuticals S.a.


USPTO Granted Patents = 65

% Expired Patents = 69.2



Trademarks = 1

Forward Citations = 321

Loading Chart...
Loading Chart...

105 inventors (with patents filed for the assignee):

goldMedal Neelima Khairatkar-Joshi (33 out of 44 patents)

silverMedal Abraham Thomas (30 out of 31 patents)

bronzeMedal Laxmikant Atmaram Gharat (22 out of 24 patents)

4.  Vidya Ganapati Kattige (13 out of 14 patents)

5.  Sukeerthi Kumar (12 out of 12 patents)

6.  Daisy Manish Shah (11 out of 12 patents)

7.  Indranil Mukhopadhyay (11 out of 11 patents)

8.  Sachin Sundarlal Chaudhari (11 out of 11 patents)

9.  Suresh Mahadev Kadam (8 out of 14 patents)

10.  Stanislas Blein (7 out of 15 patents)

11.  Malini Bajpai (7 out of 7 patents)

12.  Nagarajan Muthukaman (7 out of 8 patents)

13.  Balasubramanian Gopalan (7 out of 8 patents)

14.  Sanjib Das (6 out of 6 patents)

15.  Shailesh Ramesh Pardeshi (6 out of 6 patents)


Core Competencies:
ROR Gamma Modulators
TRPA1 Antagonists
mPGES-1 Inhibitors
Pharmaceutical Composition
Drug Delivery Device
Cannabinoid Receptor Ligands
Dipeptidyl Peptidase IV Inhibitors
Antibodies
Heterocyclic Compounds
Respiratory Disorders
Analgesic Agents
Triazolone Compounds

65 patents:

1. 10988467 - Compounds as ROR gamma modulators (2021-04-27),
2. 10709663 - Mupirocin cream in pump device (2020-07-14),
3. 10603277 - Nanoparticulate formulation comprising a TRPA1 antagonist (2020-03-31),
4. 10457649 - Polymorphs of a mPGES-1 inhibiting triazolone compound (2019-10-29),
5. 10391083 - Triazolone compounds as MPGES-1 inhibitors (2019-08-27),
6. 10344024 - Compounds as ROR gamma modulators (2019-07-09),
7. 10336688 - Carbocyclic compounds as ROR gamma modulators (2019-07-02),
8. 10213558 - Drug delivery device (2019-02-26),
9. 10189775 - Carbocyclic compounds as ROR gamma modulators (2019-01-29),
10. 10112914 - Polymorphs of a mPGES-1 inhibiting triazolone compound (2018-10-30),
11. D823460 - Anal device (2018-07-17),
12. 9975887 - Compounds as ROR gamma modulators (2018-05-22),
13. 9949955 - Triazolone compounds as mPGES-1 inhibitors (2018-04-24),
14. 9855229 - Treatment of respiratory disorders using ROR-gamma inhibitors (2018-01-02),
15. 9718817 - Aryl and heteroaryl ether compounds as ROR gamma modulators (2017-08-01),
Company Overview
Glenmark Pharmaceuticals S.A., headquartered in La Chaux-de-Fonds, Switzerland, specializes in the development and manufacturing of innovative pharmaceutical products. The company focuses on a range of therapeutic areas, particularly in the field of ROR Gamma Modulators, which are crucial for various immune-related conditions. Additionally, Glenmark is engaged in research on TRPA1 Antagonists, mPGES-1 Inhibitors, and cannabinoid receptor ligands, among other advanced pharmaceutical technologies, enhancing drug delivery and therapeutic efficacy.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Glenmark Pharmaceuticals S.a. USPTO Patent Assignee Logo
65 Patents

#2 in La Chaux-de-Fonds

#234 in Switzerland

#11,332 in the World

La Chaux-de-Fonds, CH
La Chaux-de-Fonds, Switzerland

Glenmark Pharmaceuticals S.a.

Forward Citations = 321

105 inventors:

goldMedal Neelima Khairatkar-Joshi (33 out of 44 patents)

silverMedal Abraham Thomas (30 out of 31 patents)

bronzeMedal Laxmikant Atmaram Gharat (22 out of 24 patents)

4.  Vidya Ganapati Kattige (13 out of 14 patents)

5.  Sukeerthi Kumar (12 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Glenmark Pharmaceuticals S.a.. Retrieved from https://idiyas.com/company/glenmark-pharmaceuticals-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…